Trishula Therapeutics is focused on developing innovative cancer therapies, particularly through its lead candidate, TTX-030, a first-in-class antibody that targets CD39. This antibody plays a crucial role in modulating the tumor microenvironment by inhibiting the conversion of ATP to adenosine, a process that typically promotes immune suppression. By blocking CD39, TTX-030 aims to enhance anti-tumor immunity by preventing the immunosuppressive effects of adenosine on various immune cells, including T cells and natural killer (NK) cells. The company is currently conducting multiple clinical trials to evaluate the efficacy of TTX-030 as both a standalone treatment and in combination with other therapies, such as anti-PD-1 immunotherapy and standard chemotherapy.

The therapeutic strategy employed by Trishula Therapeutics revolves around reversing the immunosuppressive conditions within the tumor microenvironment. TTX-030 not only inhibits adenosine production but also helps maintain high levels of extracellular ATP, which is essential for stimulating dendritic and myeloid-derived cells that support both innate and adaptive immune responses. This dual mechanism is designed to restore the immune system's ability to detect and combat cancer effectively. The ongoing clinical trials, including those focused on metastatic pancreatic cancer and gastric cancer, are critical for assessing the potential of TTX-030 to improve patient outcomes in these challenging malignancies.

United States

Trishula Therapeutics is a biopharmaceutical company that focuses on developing cancer therapeutics, including the first-in-class anti-CD39 antibody TTX-030.

Trishula Therapeutics

Company Details